The Antibiotic Pipeline: How “New” is New

In a recent ‘Viewpoint’ article, Dr. Fauci, Director of NIAID, mentioned that “industry has expanded the pipeline of new antibacterial drugs…with 14-agents currently in phase 3 clinical trials”.[1] Regarding the number of drugs in late development, his statement may be correct Continue reading The Antibiotic Pipeline: How “New” is New

Trial Pains Secondary to Placebo Effect?

An interesting report has just been published showing that Naloxegol is beneficial in OIC [i].  Naloxegol is a µ opioid receptor (MOR) antagonist which – by virtue of pegylation – acts peripherally and not centrally.  Hence, the analgesic effects of Continue reading Trial Pains Secondary to Placebo Effect?